Stock ESPR ESPERION THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Real-time Estimate Cboe BZX
Other stock markets
 03:15:20 2024-04-29 pm EDT 		5-day change 1st Jan Change
1.995 USD +5.00% Intraday chart for Esperion Therapeutics, Inc. +5.24% -32.78%
Mar. 25 Esperion Shares Continue Rise After Friday's FDA Approval for Nexlizet, Nexletol DJ
Mar. 25 Sector Update: Health Care Stocks Steady Premarket Monday MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Esperion to Participate in Upcoming May Investor Conferences
GL
Esperion to Report First Quarter 2024 Financial Results on May 7
GL
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL Tablets in Diverse Populations Including Women, Hispanics, Latinx and Patients with Obesity
AQ
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
AQ
Esperion Presents Important New Data from CLEAR Outcomes at ACC.24 Highlighting Value of NEXLETOL® (bempedoic acid) Tablets in Diverse Populations Including Women, Hispanics/Latinx and Patients with Obesity
GL
Esperion to Ring Nasdaq Opening Bell Today, April 1, 2024
GL
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session and Industry Expert Theatre to be presented at ACC.24
AQ
Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference
GL
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
GL
Esperion Announces Data from CLEAR Outcomes Sub-Groups as Poster Presentations, Moderated Session & Industry Expert Theatre to be Presented at ACC.24
AQ
Esperion - U.S. FDA Approves Broad New Labels for NEXLETOL and NEXLIZET to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
AQ
Esperion - CHMP Issues Positive Opinions for both Bempedoic Acid and the Bempedoic Acid, Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
AQ
U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
BU
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
GL
U.S. FDA Approves Broad New Labels for NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use
AQ
CHMP Issues Positive Opinions For Both Bempedoic Acid And The Bempedoic Acid / Ezetimibe Fixed-Dose Combination Tablet As Treatments For Hypercholesterolemia And Significantly Reducing Cardiovascular Events
GL
Esperion Therapeutics: Q4 Earnings Snapshot
AQ
Esperion Reports Fourth Quarter and Full Year 2023 Financial Results
GL
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
GL
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ESPR Stock
  4. News Esperion Therapeutics, Inc.
  5. Press Releases